Wednesday Aug 6
Dendreon Names W. Thomas Amick President and Chief Executive Officer
Most recently from 2010 to 2012, he served as chairman and chief executive officer of where, as vice president of the Ortho Biotech Oncology Franchise, he launched Procrit and built J&J's oncology franchise into a multi-billion dollar operation, making Procrit the most successful product in J&J history at the time.
Express Scripts drops 25 more drugs from its formulary
Express Scripts has announced that it will remove 25 more treatments from its 2015 list of preferred drugs, including two anemia drugs sold by Amgen Inc. Epogen and Aranesp will not be included on the formulary, but Johnson & Johnson's anemia drug, Procrit, will still be covered, Reuters reports.
UPDATE 1-Express Scripts drops Amgen anemia drugs from formulary
Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc. The company will continue to include Procrit, a similar anemia drug sold by Johnson & Johnson, on its list of preferred drugs, ... (more)
Dendreon Names New President and Chief Executive Officer
Dendreon Corporation announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately.
The Boulder County Business Report
Amgen shutting down Boulder, Longmont sites
Biologic drugmaker Amgen said Tuesday that it will lay off 12 percent to 15 percent of its worldwide workforce and close four sites, including those in Boulder and Longmont, even as it reported very strong second-quarter results that trounced Wall Street expectations.